Holen Sie sich die Stockscreener-App
53.06
4.78%
2.42
Handel nachbörslich:
53.06
Schlusskurs vom Vortag:
$50.64
Offen:
$50.77
24-Stunden-Volumen:
917.92K
Relative Volume:
1.35
Marktkapitalisierung:
$2.90B
Einnahmen:
$1.28B
Nettoeinkommen (Verlust:
$-222.15M
KGV:
-12.97
EPS:
-4.09
Netto-Cashflow:
$145.52M
1W Leistung:
+12.04%
1M Leistung:
+19.69%
6M Leistung:
+11.42%
1J Leistung:
+19.96%
1-Tages-Spanne:
$50.62
$53.38
1-Wochen-Bereich:
$47.13
$53.38
52-Wochen-Spanne:
$32.48
$57.35
Livanova Plc Stock (LIVN) Company Profile
Firmenname
Livanova Plc
Sektor
Branche
Telefon
4402033250662
Adresse
20 EASTBOURNE TERRACE, LONDON
Vergleichen Sie LIVN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LIVN
Livanova Plc
|
53.06 | 2.76B | 1.28B | -222.15M | 145.52M | -4.09 |
|
ABT
Abbott Laboratories
|
129.40 | 228.03B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
102.50 | 152.09B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
378.95 | 143.98B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.91 | 117.98B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.68 | 45.17B | 5.69B | 1.41B | 577.90M | 6.95 |
Livanova Plc Stock (LIVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-20 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-02-26 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-10-04 | Eingeleitet | Goldman | Buy |
| 2024-09-17 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-03-20 | Bestätigt | Needham | Buy |
| 2024-02-20 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Hold |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-04-14 | Eingeleitet | Mizuho | Neutral |
| 2022-12-21 | Eingeleitet | Barclays | Equal Weight |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-02-24 | Hochstufung | UBS | Neutral → Buy |
| 2021-12-03 | Eingeleitet | Goldman | Buy |
| 2021-08-20 | Bestätigt | Needham | Buy |
| 2021-07-20 | Hochstufung | Needham | Hold → Buy |
| 2021-03-03 | Herabstufung | Berenberg | Buy → Hold |
| 2021-01-05 | Herabstufung | Needham | Buy → Hold |
| 2020-09-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-06-26 | Bestätigt | Needham | Buy |
| 2019-10-30 | Bestätigt | Needham | Buy |
| 2019-02-28 | Bestätigt | Needham | Buy |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-08-02 | Bestätigt | Needham | Buy |
| 2018-06-08 | Eingeleitet | Stifel | Buy |
| 2018-05-31 | Bestätigt | Needham | Buy |
| 2018-02-28 | Bestätigt | Needham | Buy |
Alle ansehen
Livanova Plc Aktie (LIVN) Neueste Nachrichten
Single-Chamber Pacemaker Market to Reach $2.77 Billion by 2031, - openPR.com
LivaNova (LIVN) Is Up 18.7% After Strong Q2 Results and Raised 2025 Guidance – What's Changed - simplywall.st
Jefferies Reaffirms ‘Buy’ Rating on LivaNova PLC (LIVN) with $79 PT - MSN
How hedge fund analytics apply to LivaNova PLC stockAI Intraday Market Movement Prediction Tool - Newser
LivaNova PLC (NASDAQ:LIVN) Receives Average Recommendation of “Buy” from Analysts - Defense World
LivaNova PLC stock trend forecastFree High Accuracy Alerts for ROI Traders - Newser
Can machine learning forecast LivaNova PLC recoveryFree Trade Ready Stock Watch for Short Term - Newser
Chart based exit strategy for LivaNova PLCConsistent Return Setup with Exit Strategy - Newser
LivaNova (NASDAQ:LIVN) Upgraded by Wall Street Zen to “Strong-Buy” Rating - Defense World
LivaNova PLC Company Revenue and Profit Trends: A Deep DiveSmart Risk Strategy with Entry Optimization - Newser
Real time scanner hits for LivaNova PLC explainedInvestment Position Summary with Timeframe Forecast - Newser
LivaNova PLC Reports Strong Q2 Earnings and Raised Guidance - The Globe and Mail
LivaNova (LIVN) Is Up 18.0% After Raising 2025 Outlook and Advancing Core Technology Platforms - simplywall.st
LivaNova PLC (NASDAQ:LIVN) Q2 2025 Earnings Call Transcript - Insider Monkey
Goldman Sachs raises Livanova stock price target to $168 on strong 2Q25 - Investing.com UK
LivaNova raises 2025 organic growth outlook to 9%-10% with upgraded guidance for cardiopulmonary and epilepsy - MSN
Livanova stock price target raised to $65 from $55 at Mizuho - Investing.com Canada
LIVN Stock Price and Chart — NASDAQ:LIVN - TradingView
LivaNova Q2 2025 revenue increased 10.7% to USD 352.5M - Medical Buyer
Decoding LivaNova PLC (LIVN): A Strategic SWOT Insight - GuruFocus
LivaNova PLC Reports Strong Q2 2025 Results - TipRanks
LivaNova PLC (LIVN): Accelerating Growth in Neuromodulation and Cardiopulmonary Markets - AInvest
LivaNova Earnings: Strength in Cardiopulmonary Fuels Strong Second Quarter - Morningstar
LivaNova Has Found New Opportunities for Innovation in Its Strongholds - Morningstar
LivaNova Q2 2025 Earnings Call Transcript - MarketBeat
Transcript : LivaNova PLC, Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
LivaNova: Q2 Earnings Snapshot - Chron
LivaNova stock rises before hours on Q2 beats, raised guidance - MassDevice
LivaNova PLC reports results for the quarter ended June 30Earnings Summary - TradingView
LivaNova Exceeds Q2 Earnings Expectations with Robust GrowthNews and Statistics - IndexBox
LivaNova (LIVN) Q2 Earnings and Revenues Beat Estimates - Yahoo Finance
LivaNova's Outperformance and Strategic Momentum in 2025: Why Revenue, Margin Expansion, and Clinical Innovation Justify a Buy Now Position in Medical Tech - AInvest
LIVN Forecasts Higher Revenue Growth for 2025 - GuruFocus
LivaNova Q2 Adjusted Earnings, Revenue Rise; Raises 2025 Adjusted Earnings Guidance - MarketScreener
LivaNova PLC Q2 2025 Earnings: EPS of $1.05 Beats Estimate, Reve - GuruFocus
LivaNova PLC earnings beat by $0.18, revenue topped estimates - Investing.com
LivaNova results exceed second-quarter expectations - Investing.com India
LivaNova's Strategic Momentum and Clinical Innovation: A Catalyst for Sustained Growth in 2025 - AInvest
LivaNova results exceed second-quarter expectations By Investing.com - Investing.com Nigeria
LivaNova Reports Second-Quarter 2025 Results; Raises 2025 Guidan - GuruFocus
LivaNova beats estimates for Q2 revenue, raises FY guidance - MarketScreener
(LIVN) LivaNova PLC Expects FY Adjusted EPS Range $3.70$3.80 - MarketScreener
Earnings Flash (LIVN) LivaNova PLC Reports Q2 Revenue $352.5M, vs. FactSet Est of $332.2M - MarketScreener
Earnings Flash (LIVN) LivaNova PLC Posts Q2 Adjusted EPS $1.05 per Share, vs. FactSet Est of $0.87 - MarketScreener
LivaNova Reports Second-Quarter 2025 Results; Raises 2025 Guidance - TradingView
LivaNova plc (LIVN) Tops Q2 EPS by 18c ; Offers Guidance - StreetInsider
LivaNova Crushes Q2 Expectations: Revenue Jumps 11%, VNS Therapy Shows Breakthrough Results - Stock Titan
Jefferies Maintained a Buy Rating on LivaNova PLC (LIVN) - MSN
LivaNova PLC (NASDAQ:LIVN) Shares Bought by Cwm LLC - Defense World
Vicarious Surgical (NYSE:RBOT) vs. LivaNova (NASDAQ:LIVN) Head to Head Contrast - Defense World
Machine Learning Models Forecast LivaNova PLC UptickChart Driven High Reward Trading Setup Presented - metal.it
Finanzdaten der Livanova Plc-Aktie (LIVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.31%
1.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):